These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1085 related items for PubMed ID: 21455550

  • 1. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
    Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C.
    J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN.
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [Abstract] [Full Text] [Related]

  • 4. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 5. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
    Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M.
    J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 9. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.
    J Am Acad Dermatol; 2007 Apr 14; 56(4):598-603. PubMed ID: 17113190
    [Abstract] [Full Text] [Related]

  • 10. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 11. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 17; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Sep 17; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug 17; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 14. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH.
    J Drugs Dermatol; 2011 Aug 17; 10(8):878-82. PubMed ID: 21818509
    [Abstract] [Full Text] [Related]

  • 15. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators.
    Lancet; 2015 Aug 08; 386(9993):552-61. PubMed ID: 26051365
    [Abstract] [Full Text] [Related]

  • 16. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA.
    J Am Acad Dermatol; 2011 Apr 08; 64(4):671-81. PubMed ID: 21414495
    [Abstract] [Full Text] [Related]

  • 17. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 08; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 18. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K, Rogers S.
    Br J Dermatol; 2007 May 08; 156(5):1010-4. PubMed ID: 17408393
    [Abstract] [Full Text] [Related]

  • 19. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun 08; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 20. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA.
    Int J Immunopathol Pharmacol; 2006 Jun 08; 19(1):225-9. PubMed ID: 16569361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.